Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes
Tony Wawina-Bokalanga, Bert Vanmechelen, Valentine Lhermitte, Joan Martí-Carreras, Valentijn Vergote, Fara Raymond Koundouno, Joseph Akoi-Boré, Ruth Thom, Tom Tipton, Kimberley Steeds, Kéita Balla Moussa, Ablam Amento, Lies Laenen, Sophie Duraffour, Martin Gabriel, Paula Ruibal, Yper Hall, Mandy Kader-Kondé, Stephan Günther, Guy Baele, Cesar Muñoz-Fontela, Johan Van Weyenbergh, Miles W. Carroll, and Piet Maes
Author affiliations: KU Leuven, Leuven, Belgium (T. Wawina-Bokalanga, B. Vanmechelen, V. Lhermitte, J. Martí-Carreras, V. Vergote, L. Laenen, G. Baele, J. Van Weyenbergh, P. Maes); University Julius Nyerere of Kankan, Conakry, Guinea (F.R. Koudouno); Institut National de Santé Publique, Conakry (J. Akoi-Boré); Public Health England, Salisbury, UK (R. Thom, T. Tipton, K. Steeds, Y. Hall, M.W. Carroll); Centre d'Excellence de Formation et Recherche sur les Maladies Prioritaires en Guinée, Conakry (K.B. Moussa, A. Amento, M. Kader-Kondé); German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Germany (S. Duraffour, M. Gabriel); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (S. Duraffour, M. Gabriel, P. Ruibal, S. Günther, C. Muñoz-Fontela)
Main Article
Table 2
Results from multivariate logistic regression model of human leukocyte antigen class I and killer cell immunoglobulin-like receptor genes in controls and Ebola virus–infected patients, Guinea, 2015–2017
Term |
β estimate |
SE |
p value |
Intercept (β0) |
−2.27 |
0.84 |
<0.01 |
2DL2 (β1) |
2.73 |
0.82 |
<0.01 |
2DL5 (β2) |
−1.94 |
0.67 |
<0.01 |
2DS1 (β3) |
1.35 |
0.67 |
<0.05 |
2DS4–0003 (β4) |
−0.63 |
0.31 |
<0.05 |
HLA-B-Bw4-Thr (β5) |
−1.20 |
0.48 |
<0.05 |
HLA-B-Bw4-Ile (β6) |
0.76 |
0.31 |
<0.05 |
Main Article
Page created: October 16, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.